Plasma Levels of Parathyroid Hormone (1–84) Whole Molecule and Parathyroid Hormone (7–84)-Like Fragments in Pseudohypoparathyroidism Type I

PTH (7–84) has antagonistic effects on the calcemic and phosphaturic actions of PTH (1–84) whole molecule (bioPTH). Human plasma contains bioPTH and PTH (7–84)-like fragments. Using bioPTH-specific and nonspecific assays, we found that the patients with pseudohypoparathyroidism (PHP) type I with PTH...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of clinical endocrinology and metabolism 2003-05, Vol.88 (5), p.2250-2255
Hauptverfasser: Hatakeyama, Yuriko, Mizunashi, Kazutoshi, Furukawa, Yohtaro, Yabuki, Shigemitsu, Sato, Yumi, Igarashi, Teruo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2255
container_issue 5
container_start_page 2250
container_title The journal of clinical endocrinology and metabolism
container_volume 88
creator Hatakeyama, Yuriko
Mizunashi, Kazutoshi
Furukawa, Yohtaro
Yabuki, Shigemitsu
Sato, Yumi
Igarashi, Teruo
description PTH (7–84) has antagonistic effects on the calcemic and phosphaturic actions of PTH (1–84) whole molecule (bioPTH). Human plasma contains bioPTH and PTH (7–84)-like fragments. Using bioPTH-specific and nonspecific assays, we found that the patients with pseudohypoparathyroidism (PHP) type I with PTH-resistant hypocalcemia and hyperphosphatemia had the increased plasma levels of bioPTH and PTH (7–84)-like fragments than normal subjects (26.8 ± 13.2 vs. 2.37 ± 0.75 pmol/liter, P < 0.01 and 16.2 ± 8.8 vs. 0.82 ± 0.47 pmol/liter, P < 0.01, respectively). Calcitriol treatment increased phosphaturic response to PTH (1–34) (P < 0.05), and there was a negative correlation between phosphaturic response and the PTH levels (P < 0.05). These results suggested that the increased bioPTH and PTH (7–84)-like fragment levels may be related to the impaired phosphaturic response to PTH (1–34) in PHP type I. We also examined bioPTH-calcium dynamics in PHP type Ib patients and found that set-point calcium was 0.928 ± 0.045 mmol/liter and the baseline to maximal ratio of bioPTH was 0.96 ± 0.04. Calcitriol treatment increased set-point calcium to 1.129 ± 0.028 mmol/liter (P < 0.01) and suppressed baseline to maximal ratio of bioPTH to 0.35 ± 0.21 (P < 0.01). These bio-PTH calcium dynamics studies revealed the maximally stimulated baseline PTH secretion in PHP type Ib and demonstrated the effects of calcitriol on PTH-calcium curve shift and the degree of relative stimulation of baseline secretion.
doi_str_mv 10.1210/jc.2002-021610
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73239153</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73239153</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5181-c54c0bfe89f4a953fb774f9862339a15f256db449f9fc7793e3ad8f61297b2723</originalsourceid><addsrcrecordid>eNp1kc9u1DAQxi0EokvhyhH5AoJDFv9dx0dUUVppEXsogpvlOGOSbRIHO6HaG2_AgTfkSXCVlfYCljxjy79vbM-H0HNK1pRR8nbv1owQVhBGN5Q8QCuqhSwU1eohWuUDWmjFvp6hJyntCaFCSP4YnVGmmNIlW6Ffu86m3uIt_IAu4eDxzkY7NYcY2hpfhdiHAfBr-ufn71K8wV-a0AH-mIOb88IO9b95tfDFtr0FfBnttx6GKeF2wLsEcx2awxjGk7BNPb45jICvn6JH3nYJnh3zOfp8-f7m4qrYfvpwffFuWzhJS5qjcKTyUGovrJbcV0oJr8sN41xbKj2Tm7oSQnvtnVKaA7d16TeUaVXlz_Nz9GqpO8bwfYY0mb5NDrrODhDmZBRnXFPJM7heQBdDShG8GWPb23gwlJh7C8zemXsLzGJBFrw4Vp6rHuoTfux5Bl4eAZuc7Xy0g2vTiRMlEYSqzImFuwvdBDHddvMdRNOA7abGkDzERpVFvpsTmXdFnpJmmVxkMNTBxXaAMUJKZh_mOOSW_u_dfwFziLED</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73239153</pqid></control><display><type>article</type><title>Plasma Levels of Parathyroid Hormone (1–84) Whole Molecule and Parathyroid Hormone (7–84)-Like Fragments in Pseudohypoparathyroidism Type I</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Hatakeyama, Yuriko ; Mizunashi, Kazutoshi ; Furukawa, Yohtaro ; Yabuki, Shigemitsu ; Sato, Yumi ; Igarashi, Teruo</creator><creatorcontrib>Hatakeyama, Yuriko ; Mizunashi, Kazutoshi ; Furukawa, Yohtaro ; Yabuki, Shigemitsu ; Sato, Yumi ; Igarashi, Teruo</creatorcontrib><description><![CDATA[PTH (7–84) has antagonistic effects on the calcemic and phosphaturic actions of PTH (1–84) whole molecule (bioPTH). Human plasma contains bioPTH and PTH (7–84)-like fragments. Using bioPTH-specific and nonspecific assays, we found that the patients with pseudohypoparathyroidism (PHP) type I with PTH-resistant hypocalcemia and hyperphosphatemia had the increased plasma levels of bioPTH and PTH (7–84)-like fragments than normal subjects (26.8 ± 13.2 vs. 2.37 ± 0.75 pmol/liter, P < 0.01 and 16.2 ± 8.8 vs. 0.82 ± 0.47 pmol/liter, P < 0.01, respectively). Calcitriol treatment increased phosphaturic response to PTH (1–34) (P < 0.05), and there was a negative correlation between phosphaturic response and the PTH levels (P < 0.05). These results suggested that the increased bioPTH and PTH (7–84)-like fragment levels may be related to the impaired phosphaturic response to PTH (1–34) in PHP type I. We also examined bioPTH-calcium dynamics in PHP type Ib patients and found that set-point calcium was 0.928 ± 0.045 mmol/liter and the baseline to maximal ratio of bioPTH was 0.96 ± 0.04. Calcitriol treatment increased set-point calcium to 1.129 ± 0.028 mmol/liter (P < 0.01) and suppressed baseline to maximal ratio of bioPTH to 0.35 ± 0.21 (P < 0.01). These bio-PTH calcium dynamics studies revealed the maximally stimulated baseline PTH secretion in PHP type Ib and demonstrated the effects of calcitriol on PTH-calcium curve shift and the degree of relative stimulation of baseline secretion.]]></description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.2002-021610</identifier><identifier>PMID: 12727982</identifier><identifier>CODEN: JCEMAZ</identifier><language>eng</language><publisher>Bethesda, MD: Endocrine Society</publisher><subject>Adolescent ; Biological and medical sciences ; Calcitriol - administration &amp; dosage ; Calcium - blood ; Drug Resistance ; Endocrinopathies ; Female ; Humans ; Hypocalcemia - drug therapy ; Hypocalcemia - etiology ; Male ; Medical sciences ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Parathyroid Hormone - administration &amp; dosage ; Parathyroid Hormone - blood ; Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases) ; Peptide Fragments - administration &amp; dosage ; Peptide Fragments - blood ; Phosphates - blood ; Phosphates - urine ; Pseudohypoparathyroidism - blood ; Pseudohypoparathyroidism - complications ; Reference Values</subject><ispartof>The journal of clinical endocrinology and metabolism, 2003-05, Vol.88 (5), p.2250-2255</ispartof><rights>Copyright © 2003 by The Endocrine Society</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5181-c54c0bfe89f4a953fb774f9862339a15f256db449f9fc7793e3ad8f61297b2723</citedby><cites>FETCH-LOGICAL-c5181-c54c0bfe89f4a953fb774f9862339a15f256db449f9fc7793e3ad8f61297b2723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14804017$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12727982$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hatakeyama, Yuriko</creatorcontrib><creatorcontrib>Mizunashi, Kazutoshi</creatorcontrib><creatorcontrib>Furukawa, Yohtaro</creatorcontrib><creatorcontrib>Yabuki, Shigemitsu</creatorcontrib><creatorcontrib>Sato, Yumi</creatorcontrib><creatorcontrib>Igarashi, Teruo</creatorcontrib><title>Plasma Levels of Parathyroid Hormone (1–84) Whole Molecule and Parathyroid Hormone (7–84)-Like Fragments in Pseudohypoparathyroidism Type I</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description><![CDATA[PTH (7–84) has antagonistic effects on the calcemic and phosphaturic actions of PTH (1–84) whole molecule (bioPTH). Human plasma contains bioPTH and PTH (7–84)-like fragments. Using bioPTH-specific and nonspecific assays, we found that the patients with pseudohypoparathyroidism (PHP) type I with PTH-resistant hypocalcemia and hyperphosphatemia had the increased plasma levels of bioPTH and PTH (7–84)-like fragments than normal subjects (26.8 ± 13.2 vs. 2.37 ± 0.75 pmol/liter, P < 0.01 and 16.2 ± 8.8 vs. 0.82 ± 0.47 pmol/liter, P < 0.01, respectively). Calcitriol treatment increased phosphaturic response to PTH (1–34) (P < 0.05), and there was a negative correlation between phosphaturic response and the PTH levels (P < 0.05). These results suggested that the increased bioPTH and PTH (7–84)-like fragment levels may be related to the impaired phosphaturic response to PTH (1–34) in PHP type I. We also examined bioPTH-calcium dynamics in PHP type Ib patients and found that set-point calcium was 0.928 ± 0.045 mmol/liter and the baseline to maximal ratio of bioPTH was 0.96 ± 0.04. Calcitriol treatment increased set-point calcium to 1.129 ± 0.028 mmol/liter (P < 0.01) and suppressed baseline to maximal ratio of bioPTH to 0.35 ± 0.21 (P < 0.01). These bio-PTH calcium dynamics studies revealed the maximally stimulated baseline PTH secretion in PHP type Ib and demonstrated the effects of calcitriol on PTH-calcium curve shift and the degree of relative stimulation of baseline secretion.]]></description><subject>Adolescent</subject><subject>Biological and medical sciences</subject><subject>Calcitriol - administration &amp; dosage</subject><subject>Calcium - blood</subject><subject>Drug Resistance</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Humans</subject><subject>Hypocalcemia - drug therapy</subject><subject>Hypocalcemia - etiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>Parathyroid Hormone - administration &amp; dosage</subject><subject>Parathyroid Hormone - blood</subject><subject>Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases)</subject><subject>Peptide Fragments - administration &amp; dosage</subject><subject>Peptide Fragments - blood</subject><subject>Phosphates - blood</subject><subject>Phosphates - urine</subject><subject>Pseudohypoparathyroidism - blood</subject><subject>Pseudohypoparathyroidism - complications</subject><subject>Reference Values</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9u1DAQxi0EokvhyhH5AoJDFv9dx0dUUVppEXsogpvlOGOSbRIHO6HaG2_AgTfkSXCVlfYCljxjy79vbM-H0HNK1pRR8nbv1owQVhBGN5Q8QCuqhSwU1eohWuUDWmjFvp6hJyntCaFCSP4YnVGmmNIlW6Ffu86m3uIt_IAu4eDxzkY7NYcY2hpfhdiHAfBr-ufn71K8wV-a0AH-mIOb88IO9b95tfDFtr0FfBnttx6GKeF2wLsEcx2awxjGk7BNPb45jICvn6JH3nYJnh3zOfp8-f7m4qrYfvpwffFuWzhJS5qjcKTyUGovrJbcV0oJr8sN41xbKj2Tm7oSQnvtnVKaA7d16TeUaVXlz_Nz9GqpO8bwfYY0mb5NDrrODhDmZBRnXFPJM7heQBdDShG8GWPb23gwlJh7C8zemXsLzGJBFrw4Vp6rHuoTfux5Bl4eAZuc7Xy0g2vTiRMlEYSqzImFuwvdBDHddvMdRNOA7abGkDzERpVFvpsTmXdFnpJmmVxkMNTBxXaAMUJKZh_mOOSW_u_dfwFziLED</recordid><startdate>200305</startdate><enddate>200305</enddate><creator>Hatakeyama, Yuriko</creator><creator>Mizunashi, Kazutoshi</creator><creator>Furukawa, Yohtaro</creator><creator>Yabuki, Shigemitsu</creator><creator>Sato, Yumi</creator><creator>Igarashi, Teruo</creator><general>Endocrine Society</general><general>Copyright by The Endocrine Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200305</creationdate><title>Plasma Levels of Parathyroid Hormone (1–84) Whole Molecule and Parathyroid Hormone (7–84)-Like Fragments in Pseudohypoparathyroidism Type I</title><author>Hatakeyama, Yuriko ; Mizunashi, Kazutoshi ; Furukawa, Yohtaro ; Yabuki, Shigemitsu ; Sato, Yumi ; Igarashi, Teruo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5181-c54c0bfe89f4a953fb774f9862339a15f256db449f9fc7793e3ad8f61297b2723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Biological and medical sciences</topic><topic>Calcitriol - administration &amp; dosage</topic><topic>Calcium - blood</topic><topic>Drug Resistance</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Humans</topic><topic>Hypocalcemia - drug therapy</topic><topic>Hypocalcemia - etiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>Parathyroid Hormone - administration &amp; dosage</topic><topic>Parathyroid Hormone - blood</topic><topic>Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases)</topic><topic>Peptide Fragments - administration &amp; dosage</topic><topic>Peptide Fragments - blood</topic><topic>Phosphates - blood</topic><topic>Phosphates - urine</topic><topic>Pseudohypoparathyroidism - blood</topic><topic>Pseudohypoparathyroidism - complications</topic><topic>Reference Values</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hatakeyama, Yuriko</creatorcontrib><creatorcontrib>Mizunashi, Kazutoshi</creatorcontrib><creatorcontrib>Furukawa, Yohtaro</creatorcontrib><creatorcontrib>Yabuki, Shigemitsu</creatorcontrib><creatorcontrib>Sato, Yumi</creatorcontrib><creatorcontrib>Igarashi, Teruo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hatakeyama, Yuriko</au><au>Mizunashi, Kazutoshi</au><au>Furukawa, Yohtaro</au><au>Yabuki, Shigemitsu</au><au>Sato, Yumi</au><au>Igarashi, Teruo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma Levels of Parathyroid Hormone (1–84) Whole Molecule and Parathyroid Hormone (7–84)-Like Fragments in Pseudohypoparathyroidism Type I</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2003-05</date><risdate>2003</risdate><volume>88</volume><issue>5</issue><spage>2250</spage><epage>2255</epage><pages>2250-2255</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><coden>JCEMAZ</coden><abstract><![CDATA[PTH (7–84) has antagonistic effects on the calcemic and phosphaturic actions of PTH (1–84) whole molecule (bioPTH). Human plasma contains bioPTH and PTH (7–84)-like fragments. Using bioPTH-specific and nonspecific assays, we found that the patients with pseudohypoparathyroidism (PHP) type I with PTH-resistant hypocalcemia and hyperphosphatemia had the increased plasma levels of bioPTH and PTH (7–84)-like fragments than normal subjects (26.8 ± 13.2 vs. 2.37 ± 0.75 pmol/liter, P < 0.01 and 16.2 ± 8.8 vs. 0.82 ± 0.47 pmol/liter, P < 0.01, respectively). Calcitriol treatment increased phosphaturic response to PTH (1–34) (P < 0.05), and there was a negative correlation between phosphaturic response and the PTH levels (P < 0.05). These results suggested that the increased bioPTH and PTH (7–84)-like fragment levels may be related to the impaired phosphaturic response to PTH (1–34) in PHP type I. We also examined bioPTH-calcium dynamics in PHP type Ib patients and found that set-point calcium was 0.928 ± 0.045 mmol/liter and the baseline to maximal ratio of bioPTH was 0.96 ± 0.04. Calcitriol treatment increased set-point calcium to 1.129 ± 0.028 mmol/liter (P < 0.01) and suppressed baseline to maximal ratio of bioPTH to 0.35 ± 0.21 (P < 0.01). These bio-PTH calcium dynamics studies revealed the maximally stimulated baseline PTH secretion in PHP type Ib and demonstrated the effects of calcitriol on PTH-calcium curve shift and the degree of relative stimulation of baseline secretion.]]></abstract><cop>Bethesda, MD</cop><pub>Endocrine Society</pub><pmid>12727982</pmid><doi>10.1210/jc.2002-021610</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-972X
ispartof The journal of clinical endocrinology and metabolism, 2003-05, Vol.88 (5), p.2250-2255
issn 0021-972X
1945-7197
language eng
recordid cdi_proquest_miscellaneous_73239153
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals
subjects Adolescent
Biological and medical sciences
Calcitriol - administration & dosage
Calcium - blood
Drug Resistance
Endocrinopathies
Female
Humans
Hypocalcemia - drug therapy
Hypocalcemia - etiology
Male
Medical sciences
Non tumoral diseases. Target tissue resistance. Benign neoplasms
Parathyroid Hormone - administration & dosage
Parathyroid Hormone - blood
Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases)
Peptide Fragments - administration & dosage
Peptide Fragments - blood
Phosphates - blood
Phosphates - urine
Pseudohypoparathyroidism - blood
Pseudohypoparathyroidism - complications
Reference Values
title Plasma Levels of Parathyroid Hormone (1–84) Whole Molecule and Parathyroid Hormone (7–84)-Like Fragments in Pseudohypoparathyroidism Type I
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T03%3A45%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20Levels%20of%20Parathyroid%20Hormone%20(1%E2%80%9384)%20Whole%20Molecule%20and%20Parathyroid%20Hormone%20(7%E2%80%9384)-Like%20Fragments%20in%20Pseudohypoparathyroidism%20Type%20I&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Hatakeyama,%20Yuriko&rft.date=2003-05&rft.volume=88&rft.issue=5&rft.spage=2250&rft.epage=2255&rft.pages=2250-2255&rft.issn=0021-972X&rft.eissn=1945-7197&rft.coden=JCEMAZ&rft_id=info:doi/10.1210/jc.2002-021610&rft_dat=%3Cproquest_cross%3E73239153%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73239153&rft_id=info:pmid/12727982&rfr_iscdi=true